June 4, 2024
* New FDA-cleared AI-enabled applications include the industry's first
automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronary artery disease and cardio-

    oncology issues in seconds
  * First fully automated 3D quantification of mitral regurgitation (MR)
    volumes* designed to provide reproducible, efficient analysis helps
    clinicians make better-informed decisions for patients with heart valve
    disease

Amsterdam, the Netherlands - Royal Philips (http://www.philips.com/newscenter)
(NYSE: PHG, AEX: PHIA), a global leader in health technology, announced its
next-generation AI-enabled cardiovascular ultrasound platform to help speed up
cardiac ultrasound analysis with proven AI technology and reduce the burden on
echocardiography labs. Integrated into the company's EPIQ CVx and Affiniti CVx
ultrasound systems, the new FDA 510(k) cleared AI applications significantly
advance Philips' cardiovascular imaging and diagnosis solutions, automating
measurements and speeding workflows to increase productivity.
Heart failure is a rapidly growing health issue that affects an estimated 64
million people worldwide (1). It's also associated with high mortality and poor
quality of life, and is a substantial burden on healthcare systems globally (2).
As the most common and least invasive way to check the structure and function of
the heart, cardiovascular ultrasound has played a key role in diagnosing cardiac
disease earlier.
"As clinical cases get more complex and patient volumes increase, we read
hundreds of echocardiography exams daily with thousands of data points," said
Roberto Lang, MD, Director of the Noninvasive Cardiac Imaging Lab, University of
Chicago Medicine, USA. "With the integration of AI into echocardiography
solutions, we can now automate some of the steps to support clinicians'
decision-making, allowing them to detect, diagnose, and monitor various cardiac
conditions with greater confidence and efficiency in seconds."
Dr. Lang will join other clinicians to share the results of a new scientific
abstract being presented at the American Society of Echocardiography (ASE2024
(https://www.asescientificsessions.org/)) annual meeting (June 14 - 16,
Portland, US), demonstrating how first-of-kind AI algorithms co-developed with
Philips provide highly accurate detection of regional wall motion abnormalities
(RWMA) on echocardiography. RWMAs can be an independent indicator of adverse
cardiovascular events and death in patients with cardiovascular diseases
like myocardial infarction (MI) and congenital heart disease. Automated machine
learning-based assessment of RWMA has the potential to improve the efficiency of
all readers. "An advantage of AI methods over conventional visual analysis is
that it can be performed in seconds, providing rapid and accurate information to
help augment expert reads by quickly highlighting areas of concern for RWMA,
improving the ease and efficiency of interpretation," Lang added.
"By harnessing the power of AI into our echocardiography solutions, we empower
clinicians with enhanced diagnostic capabilities, to ultimately improve patient
care and outcomes in the management of coronary and valvular disease, while
enhancing overall efficiency in cardiac practice," said David Handler, VP and
Business Leader for Global Cardiovascular Ultrasound at Philips. "For patients,
this means consistent image interpretation which can lead to fewer re-scans,
shorter and more effective interventional procedures, and potentially faster
recovery times."
Integration of proven AI applications from Philips DiA Imaging Analysis
Trained on anonymized patient data sets from real-life clinical environments,
the AI features integrated across Philips cardiovascular ultrasound systems help
improve the quality and reproducibility of cardiac imaging and enhance operator
and departmental efficiency. These include FDA-cleared and CE-marked software
solutions from DiA Imaging Analysis, a Philips company. Together, these AI
features automate how users interpret ultrasound images, so clinicians with
varying levels of ultrasound experience can automatically analyze images with
increased speed, efficiency, and accuracy in real time.
In addition to integrating these latest advanced AI features into the company's
cardiovascular ultrasound systems, Philips' new mini ultrasound transducer X11
4t (https://www.usa.philips.com/a-
w/about/news/archive/standard/news/press/2024/new-philips-mini-tee-ultrasound-
transducer-helps-improve-cardiac-care-for-more-patients.html), introduced
earlier this year, is fully compatible with the EPIQ CVx and Affiniti CVx
systems. The innovative transducer allows interventional cardiologists to
provide enhanced care to a wider range of patients, including pediatric patients
as small as 5kg in weight.
Through breakthrough innovation and collaborations with technology leaders
including NVIDIA (https://www.nvidia.com/en-us/on-demand/session/gtcfall21-
a31313/)**, Philips continues to rapidly integrate AI into its cardiovascular
ultrasound portfolio to help improve efficiency and productivity and mitigate
staff shortages while delivering high-quality cardiology care to an increasing
number of patients. These third-party solutions complement Philips' proprietary
AI-enabled solutions (https://www.philips.com/a-w/about/artificial-
intelligence.html), integrating AI to enhance diagnostic confidence and
decision-making.
For more information, join Philips in Booth #441 at ASE2024
(https://www.asescientificsessions.org/) and visit Philips Cardiovascular
Ultrasound
(https://www.usa.philips.com/healthcare/solutions/ultrasound/cardiovascular-
ultrasound) for the latest AI-powered echocardiography applications.
*Clinical performance and safety have not been established for some features
which have 510(k) pending. Not available for sale in the USA.
**NVIDIA MONAI for medical imaging AI and NVIDIA Holoscan for building software-
defined medical devices.
(1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398425/
(2) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398425/
For further information, please contact:
Kathy O'Reilly
Philips Global External Relations
Tel.: +1 978 221 8919
E-mail : kathy.oreilly@philips.com (mailto:kathy.oreilly@philips.com)
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and well-being through meaningful
innovation. Philips' patient- and people-centric innovation leverages advanced
technology and deep clinical and consumer insights to deliver personal health
solutions for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-
guided therapy, monitoring, and enterprise informatics, as well as in personal
health. Philips generated 2023 sales of EUR 18.2 billion and employs
approximately 69,100 employees with sales and services in more than 100
countries. News about Philips can be found at www.philips.com/newscenter
(http://www.philips.com/newscenter).
Â